Sales & Marketing News | pharmaphorum

News

Pressure raises on Illumina as FTC orders it to shed Grail

The Federal Trade Commission has ordered Illumina to divest Grail, the cancer detection business it bought for $7.1 billion in 2021, saying it will “stifle” competition an

News

J&J raises talc offer to $9bn with new insolvency bid

Johnson & Johnson has made an offer of nearly $9 billion to try to resolve tens of thousands of lawsuits it faces in the US that claim its talc products cause cancer.&

News

Okyo Pharma abandons UK listing in favour of Nasdaq

Okyo Pharma has decided to delist its shares from the London Stock Exchange and list them on the Nasdaq in New York, blaming “negligible” trading that doesn’t justify the

News

FDA clears Keytruda/Padcev regimen for bladder cancer

The combination of Merck & Co’s checkpoint inhibitor Keytruda and Seagen/Astellas’ antibody-drug conjugate Padcev has been approved by the FDA as an alternative to che

News

J&J’s bankruptcy bid to resolve talc claims blocked

Johnson & Johnson’s attempt to draw a line under the ongoing litigation it faces over allegations that its talc products cause cancer has been blocked by an appeals co

News

US government says SCOTUS should hear ‘skinny label’ case

The White House has told the US Supreme Court that it should hear a hotly-contested lawsuit between Teva and GSK that could have ramifications on the ability of generic dr

Pressure raises on Illumina as FTC orders it to shed Grail

J&J raises talc offer to $9bn with new insolvency bid

Okyo Pharma abandons UK listing in favour of Nasdaq

FDA clears Keytruda/Padcev regimen for bladder cancer

J&J’s bankruptcy bid to resolve talc claims blocked

US government says SCOTUS should hear ‘skinny label’ case

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks